What Is a Jada Device? Treatment for Postpartum Bleeding

The Jada device is an intrauterine vacuum system designed to stop dangerous bleeding after childbirth. Cleared by the FDA in 2020, it works by applying gentle suction inside the uterus to help it contract and seal off open blood vessels, addressing the most common cause of postpartum hemorrhage: a uterus that fails to clamp down on its own after delivery. The device represents a shift in how clinicians manage severe postpartum bleeding, and growing real-world data suggest it may offer advantages over older approaches like balloon tamponade.

Why Postpartum Bleeding Can Become an Emergency

During pregnancy, blood flow to the uterus increases dramatically to support the placenta. After the placenta separates from the uterine wall during delivery, the muscle fibers of the uterus are supposed to contract tightly, squeezing those exposed blood vessels shut. When the uterus does not contract firmly enough, a condition called uterine atony, blood can pour from the open vessel sites at an alarming rate. Uterine atony accounts for up to about 80% of postpartum hemorrhage cases.¹

The standard first response is uterotonic medications, drugs that stimulate the uterine muscles to contract. Oxytocin, misoprostol, and methylergonovine are commonly used. But when medications alone do not control the bleeding, clinicians need a second-line intervention, and fast. Historically, that has meant placing a fluid-filled balloon inside the uterus (uterine balloon tamponade), packing the uterus with gauze, or in severe cases, proceeding to surgery. The Jada device was developed to fill this gap between medications and more invasive procedures.

How the Jada Device Works

The Jada system consists of a silicone loop that sits inside the uterine cavity, connected to a tube that runs through the cervix and attaches to a wall suction source, equipment already present in virtually every labor and delivery unit. Once the loop is positioned inside the uterus, low-level vacuum is applied. This suction collapses the uterine walls inward, pulling them together and mechanically compressing the open blood vessels at the placental site.²

The key idea is that the vacuum does not just passively press against bleeding tissue the way a balloon does. Instead, it actively draws the uterine walls together, mimicking and reinforcing the natural contraction process. With the cavity collapsed and the immediate hemorrhage slowed, clinicians have time for uterotonic medications to take full effect and for the uterus to sustain its own contractions. Once the uterus maintains tone on its own, the vacuum is weaned off and the device is removed.

Placement is relatively straightforward. The silicone loop is inserted through the cervix, either vaginally after a vaginal birth or through the uterine incision during a cesarean delivery. Because the device connects to standard hospital wall suction, it does not require specialized equipment beyond the device itself. Early reviews have noted its reported ease of use and short treatment duration as practical advantages in urgent clinical scenarios.³

Effectiveness in Real-World Use

The most substantial body of evidence for the Jada device comes from the RUBY registry, a large observational dataset tracking real-world outcomes across multiple hospitals. An analysis of 800 patients from this registry found an overall success rate of roughly 89.5%, where success meant that bleeding was controlled without needing to escalate to a more invasive procedure like surgery.⁴

When the results are broken down by delivery type, the device performed somewhat better after vaginal births than after cesarean deliveries. In a large real-world utilization study, bleeding was successfully controlled in about 92.5% of vaginal birth cases and about 84% of cesarean birth cases.⁵ The highest success rates were seen in isolated uterine atony: roughly 96% for vaginal births and 88% for cesarean births when atony was the sole cause of hemorrhage.⁵

Two patterns emerge from the data. First, the underlying cause of bleeding matters. When uterine atony is the primary problem, the device works best, which makes sense given that the vacuum mechanism directly supports uterine contraction. When bleeding has mixed causes or stems from something other than atony, success rates are somewhat lower. Second, timing of placement matters. Outcomes were better when the device was inserted before cumulative blood loss exceeded 2,000 milliliters, reinforcing the general principle in hemorrhage management that earlier intervention tends to produce better results.⁴

How It Compares to Balloon Tamponade

For years, the go-to intrauterine device for postpartum hemorrhage has been uterine balloon tamponade, where a balloon (often a Bakri balloon) is inserted into the uterus and inflated with saline to press against bleeding surfaces. The Jada device approaches the same problem from the opposite direction: instead of pushing outward, it pulls inward. Comparative trials between the two are still lacking, but emerging evidence suggests vacuum-induced hemorrhage control is a promising alternative as a second-line therapy.⁶

A retrospective cohort study comparing the two devices found several differences in vaginal deliveries. Women treated with the vacuum device had lower overall blood loss (a median of about 2,050 mL versus about 2,390 mL with the balloon), lower rates of red blood cell transfusion (roughly 53% versus 80%), and zero device expulsions, compared to about 14% expulsion with the balloon.⁷ For cesarean deliveries, the differences in blood loss and transfusion rates were not statistically significant between the two devices.

One practical difference that stood out was how long the device stayed in place. The vacuum device had markedly shorter indwelling times in both vaginal and cesarean deliveries. After vaginal birth, the median time was about 4.3 hours for the vacuum device versus nearly 14 hours for the balloon. After cesarean delivery, it was about 3 hours versus nearly 14 hours.⁷ A shorter indwelling time has practical implications for the patient’s comfort, mobility, and overall recovery experience. Rates of massive transfusion, the most extreme marker of uncontrolled hemorrhage, did not significantly differ between the two devices in either delivery type.

It is worth noting that this was a retrospective study, not a randomized trial, so the two groups of patients may have differed in ways beyond which device they received. Randomized head-to-head trials are the gold standard for these comparisons and are still needed.

Safety Profile

Across the available studies, the safety record of the Jada device has been reassuring. In the large real-world utilization study, only three serious adverse events were deemed possibly related to the device or procedure, out of hundreds of treated patients.⁸ No uterine perforations or device expulsions have been reported in the published real-world data, which is a meaningful distinction from balloon tamponade, where balloon displacement is a recognized complication.

In preterm deliveries, a setting where the uterus is smaller and clinicians might worry about injury, the device was similarly well tolerated. Among deliveries before 28 weeks and between 28 and 34 weeks, there were no maternal deaths, uterine perforations, device expulsions, or serious device-related adverse effects.⁹ Researchers have recommended careful assessment of uterine size before insertion in very preterm births, but the data so far have not flagged specific safety concerns in this population.⁴

As with any device inserted into the uterus shortly after delivery, there are theoretical risks of infection, tissue injury, and retained fragments. The published studies have not raised alarm bells on these fronts, but longer-term surveillance and larger datasets will continue to refine the safety picture.

Use in Preterm Births

Postpartum hemorrhage is not limited to full-term deliveries, and treating it in preterm births brings unique challenges. The uterus is smaller, the tissues may behave differently, and there is less clinical experience to draw on. The Jada device has been specifically studied in this setting. In births before 28 weeks, treatment success was about 86%, and in births between 28 and 34 weeks, it was about 89%.⁹ These figures were comparable to the success rates seen in term deliveries, which is encouraging.

Among very early preterm vaginal births (before 28 weeks), the success rate was about 82%, while all three cesarean cases in that group were successfully treated. In the 28-to-34-week group, all 13 vaginal birth cases were successfully treated, and about 83% of cesarean cases.⁹ The sample sizes here are small, so these percentages should be interpreted cautiously. But the absence of serious complications in these early deliveries is meaningful data for clinicians who may need an option beyond medications for a preterm patient who is hemorrhaging.

When the Device Does Not Work

No hemorrhage-control device works every time, and understanding what happens when the Jada device fails is important for clinicians and patients alike. In roughly 10-15% of cases across studies, bleeding was not controlled and clinicians needed to escalate to additional interventions. Those escalation options include uterine compression sutures (stitches placed surgically to physically compress the uterus), uterine artery embolization (a radiologic procedure to block blood flow), or hysterectomy as a last resort.

The cases where the device is less likely to succeed tend to involve bleeding that is not purely from uterine atony. When hemorrhage has multiple contributing causes, such as cervical or vaginal lacerations alongside a poorly contracting uterus, or when it stems from retained placental tissue or abnormal placentation, the vacuum mechanism alone cannot address the underlying problem. This makes sense intuitively: the device helps the uterus contract, so conditions where contraction is the core issue respond best. It does not repair torn tissue or remove retained fragments. Identifying the cause of bleeding before or shortly after device placement helps clinicians decide whether the vacuum approach is likely to be sufficient or whether they need to pursue other interventions simultaneously.

Cost Implications for Hospitals

Postpartum hemorrhage is expensive to manage. Blood transfusions, ICU admissions, surgical interventions, and extended hospital stays all drive up costs. If a device can reduce the likelihood of these downstream events, it may offset its own cost even if its upfront price is higher than simpler alternatives.

An economic evaluation modeling a hypothetical cohort of 10,000 births estimated that using the vacuum device instead of balloon tamponade as the primary second-line therapy could reduce ICU admissions by about 2%, hysterectomy rates by about 2%, and major blood transfusions by roughly 5%. The projected annual cost savings from these reductions were substantial, totaling well over $1 million across the three categories combined.¹⁰

A budget impact analysis from Germany reached similar conclusions, finding per-case cost savings ranging from roughly €184 to €921 depending on the severity subgroup, with the greatest savings in more severe hemorrhage cases where avoiding transfusions and surgery has the biggest financial impact.¹¹ These are modeled estimates rather than direct measurements of actual spending, so real-world cost impact will depend on how hospitals integrate the device into their protocols and how frequently it successfully averts more expensive interventions.

Where It Fits in Treatment Algorithms

The Jada device is positioned as a second-line intervention, meaning it comes after first-line uterotonic medications have been tried and found insufficient. In practice, many labor and delivery units are incorporating it into their hemorrhage protocols alongside or in place of balloon tamponade. The device does not replace medications; uterotonics are still given simultaneously. And it does not replace surgery when surgery is needed. It occupies the space between “the drugs aren’t enough” and “we need to go to the operating room.”

For hospitals considering adoption, training is a practical factor. The device connects to existing wall suction, which eliminates the need for new infrastructure, but clinicians still need to learn proper placement technique, appropriate vacuum levels, and weaning protocols. Simulation-based training has become a common approach for onboarding labor and delivery teams. Because the device is relatively new, many institutions are still in the process of building institutional experience and updating their hemorrhage bundles to include it as an option.

Global Access and Low-Resource Settings

Postpartum hemorrhage is a leading cause of maternal death worldwide, and the burden falls disproportionately on low- and middle-income countries where access to surgical intervention, blood products, and intensive care is limited. A device that can control hemorrhage quickly, using only wall suction or even a manual suction source, has obvious appeal in these settings.

However, awareness and accessibility remain uneven. A modified Delphi study examining global research priorities for intrauterine hemorrhage-control tools found that clinicians in high-income countries showed greater interest in the Jada system than their counterparts in low- and middle-income countries. The researchers noted this may reflect the device’s FDA approval and greater awareness in wealthier health systems, or it could reflect concerns among clinicians in resource-limited settings about insertion challenges and device availability.¹²

Simpler suction-based and sponge-based devices are also under investigation for low-resource settings, and the broader principle of intrauterine vacuum for hemorrhage control may eventually be adapted into forms that are more affordable and easier to deploy without hospital-grade suction infrastructure. For now, the Jada device itself is primarily used in well-equipped hospital settings in higher-income countries, and how this technology evolves for use in the places where maternal hemorrhage deaths are most concentrated remains an open and urgent question.